- Home
- ADCT
ADCT
ADC Therapeutics SA
as 05-09-2025 4:00pm EST
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).
Upcoming Earnings Alert:
Get ready for potential market movements as ADC Therapeutics SA ADCT prepares to release earnings report on 14 May 2025.
| Founded: | 2011 | Country: | Switzerland |
| Employees: | N/A | City: | EPALINGES |
| Market Cap: | 127.9M | IPO Year: | 2020 |
| Target Price: | $7.75 | AVG Volume (30 days): | 235.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.62 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.05 - $4.83 | Next Earning Date: | 05-14-2025 |
| Revenue: | $70,837,000 | Revenue Growth: | 1.84% |
| Revenue Growth (this year): | 6.82% | Revenue Growth (next year): | 18.56% |
Latest ADC Therapeutics SA News
ADCT Breaking Stock News: Dive into ADCT Ticker-Specific Updates for Smart Investing
Zacks
a day ago
Zymeworks Inc. (ZYME) Reports Q1 Loss, Tops Revenue Estimates
PR Newswire
a day ago
ADC Therapeutics to Host First Quarter 2025 Financial Results Conference Call on May 14, 2025
Zacks
8 days ago
Kura Oncology (KURA) Reports Q1 Loss, Lags Revenue Estimates
Zacks
9 days ago
AC Immune (ACIU) Reports Q1 Loss, Lags Revenue Estimates
Zacks
10 days ago
Agenus (AGEN) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Zacks
11 days ago
ADC Therapeutics SA (ADCT) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
PR Newswire
11 days ago
ADC Therapeutics Announces Preclinical Data Highlighted at the American Association for Cancer Research Annual Meeting 2025
PR Newswire
a month ago
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
Compare ADCT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ADCT ADC Therapeutics SA - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.